BTK and B-cell chronic lymphocytic leukemia: While the utility of drug classes such as ROR1 antibodies, MCL1 inhibitors, BTK protein degraders, and immunotherapies (bispecific antibodies, chimeric antigen receptor [CAR] T-cell therapy) are being explored in relapsed/refractory (R/R) CLL, none are expected to imminently impact 1L therapeutic selection [17].